Zobrazení zdroje stránky Emeryregan4633

Quantum dots (QDs) are luminescent semiconductor nanomaterials (NMs) with various biomedical applications, but the high toxicity associated with traditional QDs, such as Cd-based QDs, limits their uses in biomedicine. As such, the development of biocompatible metal-free QDs has gained extensive research interests. In this study, we synthesized near-infrared emission Cu, N-doped carbon dots (CDs) with optimal emission at 640 nm and a fluorescence quantum yield of 27.1% (in N,N-dimethylformamide [DMF]) by solvothermal method using o-phenylenediamine and copper acetate monohydrate. We thoroughly characterized the CDs and showed that they were highly fluorescent and stable under different conditions, although in highly acidic (pH = 1-2) or alkaline (pH = 12-13) solutions, a redshift or blueshift of fluorescence emission peak of Cu, N-doped CDs was also observed. When exposed to human umbilical vein endothelial cells (HUVECs), Cu, N-doped CDs only significantly induced cytotoxicity at very high concentrations (100 or 200 μg/ml), but their cytotoxicity appeared to be comparable with carbon black (CB) nanoparticles (NPs) at the same mass concentrations. As the mechanisms, 200 μg/ml Cu, N-doped CDs and CB NPs promoted endoplasmic reticulum (ER) stress proteins IRE1α and chop, leading to increased cleaved caspase 3/pro-caspase 3 ratio, but CB NPs were more effective. [https://www.selleckchem.com/products/4-octyl-Itaconate.html 4-Octyl molecular weight] At noncytotoxic concentration (50 μg/ml), Cu, N-doped CDs successfully labeled HUVECs. In summary, we successfully prepared highly fluorescent and relatively biocompatible CDs to label HUVECs in vitro.<br /><br /> The aim of this study was to identify the best combination of plant growth promoting bacteria (PGPB) and arbuscular mycorrhizal fungi (AMF) for biofortification and enhancing yield in wheat as well as improve soil health under field conditions. Another aim was to get insights into metabolite dynamics in plants treated with PGPB and AMF.<br /><br /> Different combinations of PGPB and AMF that gave good results in greenhouse study were used in a field study. The combined application of Bacillus subtilis CP4 (native PGPB) and AMF gave the best results with a significant increase in biomass, macronutrient and micronutrient content in wheat grains and improvement in yield-related parameters relative to the untreated control. PGPB and AMF treatment increased antioxidant enzymes and compounds and decreased the level of an oxidation marker. Metabolite profiling performed using Gas Chromatography-Mass Spectrometry (GC-MS) showed significant upregulation of specific organic acids, amino acids, sugars and sugar alcohols in planzer to enhance wheat nutrient content and production and soil health thereby advancing agriculture.The upgrading of plastic waste is one of the grand challenges for the 21st century owing to its disruptive impact on the environment. Here, we show the first example of the upgrading of various aromatic plastic wastes with C-O and/or C-C linkages to arenes (75-85 % yield) via catalytic hydrogenolysis over a Ru/Nb2 O5 catalyst. This catalyst not only allows the selective conversion of single-component aromatic plastic, and more importantly, enables the simultaneous conversion of a mixture of aromatic plastic to arenes. The excellent performance is attributed to unique features including (1) the small sized Ru clusters on Nb2 O5 , which prevent the adsorption of aromatic ring and its hydrogenation; (2) the strong oxygen affinity of NbOx species for C-O bond activation and Brønsted acid sites for C-C bond activation. This study offers a catalytic path to integrate aromatic plastic waste back into the supply chain of plastic production under the context of circular economy.<br /><br /> To summarize evidence from randomized controlled trials (RCTs) concerning the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on kidney outcomes in patients with type 2 diabetes mellitus (T2DM).<br /><br /> The Medline, EMBASE and Cochrane databases were searched for RCTs comparing DPP-4 inhibitors with a placebo, active comparator or standard care, with at least 500 person-years follow-up in patients with T2DM and with reporting of kidney outcomes. Treatment effects were summarized using random-effects meta-analysis.<br /><br /> Ten trials including 47 955 patients (mean estimated glomerular filtration rate [eGFR] 71 mL/min/1.73m<br /><br /> , mean follow-up 10 762 patient-years per trial) were eligible for inclusion. DPP-4 inhibitors were compared with placebo (five trials), active comparator (three trials), and standard care (two trials). Overall, treatment with DPP-4 inhibitors was associated with a greater decline in eGFR than treatment with the comparators (weighted mean difference -1.12 mL/min/1.73m<br /><br /> , 95% confidence intervpeptidase-4 inhibitors are associated with a greater decline in eGFR, despite reducing the development and progression of albuminuria, and have no clear effect on other key kidney outcomes.<br /><br /> To investigate the ability of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (TRS-HF<br /><br /> ) to stratify patients with type 2 diabetes mellitus (T2DM) and high cardiovascular risk for heart failure (HF) hospitalization.<br /><br /> We used data from the control group of the Action to Control Cardiovascular Risk in Diabetes Study Group (ACCORD) trial (n = 5123; mean follow-up 4.8 years). The TRS-HF<br /><br /> includes prior HF (2 points), atrial fibrillation (1 point), coronary artery disease (1 point), estimated glomerular filtration rate &lt;60 mL/min/1.73 m<br /><br /> (1 point), and urine albumin-to-creatinine ratio (&gt;300 mg/g 2 points; 30-300 mg/g 1 point). We evaluated the discrimination (Harrell's C-index) and calibration (Nam-D'Agostino calibration statistic) of the TRS-HF<br /><br /> with regard to time to HF hospitalization or death due to HF.<br /><br /> The mean age of the participants was 62.8 ± 6.6 years, and 38% were women. The prevalences of TRS-HF<br /><br /> 0, 1, 2, 3 and ≥4 were 42.1%, 34.9%, 14.6%, 6.0% and 2.5%, respectively. Increasing TRS-HF<br /><br /> corresponded to an increasing HF risk 1.3 per 1000 person-years for a TRS-HF<br /><br /> of 0 to 64.7 per 1000 person-years for TRS-HF<br /><br /> of ≥4. The TRS-HF<br /><br /> demonstrated robust discrimination of HF outcomes (C-index 0.78). Furthermore, the score was well calibrated for HF outcomes (calibration statistic P = 0.13). Similar results were seen in participants without baseline HF (C-index 0.75).<br /><br /> The TRS-HF<br /><br /> discriminates HF-specific risk among people with T2DM. The use of TRS-HF<br /><br /> to identify those who would maximally benefit from therapies that reduce HF risk warrants evaluation.<br /><br />The TRS-HFDM discriminates HF-specific risk among people with T2DM. The use of TRS-HFDM to identify those who would maximally benefit from therapies that reduce HF risk warrants evaluation.